PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

Myomo, Inc.

PosiFunda Ratios Only on PositoAI

PositoAI's own ratios from Myomo, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.

What stands out

  • Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.

Where $100 of sales goes

$135Operating costs$1.1Interest$38Net loss

Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.

Cash quality

Profit Cash Ratio

—

Loss-making or profit too small

Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.

Self-Funding Ratio

-5.0×

Over the last 3 years operating cash was negative while the company kept spending on investment (capex).

Higher than 55% of Healthcare companies in United States.

Cash Locked Ratio

$12

For every $100 of sales, $12 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $17 tied up three years earlier.

Less money tied up than 76% of Healthcare companies in United States.

Growth quality

Steadiness Ratio

3/3 · 2/3

Sales grew in 3 of the last 3 years; profit grew in 2 of 3.

Steadier than 85% of Healthcare companies in United States.

Growth Efficiency Ratio

−$19

Sales grew 163% in 3 years, but profit fell: $19 less profit per $100 of extra sales.

Lower than 76% of Healthcare companies in United States.

Asset Productivity Ratio

+163% / +280%

In 3 years sales changed by +163% while total assets changed by +280%. Assets grew faster than sales.

Balance-sheet strength

Debt Due Cover Ratio

-29.3×

Operating cash was negative last year, while some debt falls due within a year.

Lower than 63% of Healthcare companies in United States.

Cash Cushion Ratio

−2%

Debt, after subtracting cash, equals 2% of its market value (net debt).

Lower than 70% of Healthcare companies in United States.

Tangible Assets Ratio

96%

Of every $100 the company owns, $96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.

More tangible than 76% of Healthcare companies in United States.

Tangible Net Worth Ratio

86%

Of every $100 of net worth, $86 is tangible; the rest is goodwill and other intangibles, often from buying other companies.

More tangible than 67% of Healthcare companies in United States.

Shareholders

Shareholder Slice Ratio

+396%

Share count rose 396% in 3 years, so each share's slice of the company became smaller.

Bigger rise in share count than 84% of Healthcare companies in United States.

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (13)

Myomo, Inc. made a loss over the last year. Myomo, Inc. owes $0.84 for every $1 it owns. Myomo, Inc. made a loss in each of the last two years.

Compared with Healthcare companies in United States · latest annual results Dec 2025.

P/E ratio

Loss

Myomo, Inc. made a loss over the last year, so its P/E ratio is not meaningful.

P/B ratio

8.29

The share price is 8.29 times Myomo, Inc.'s book value per share, higher than 83% of Healthcare companies in United States.

Market cap

$48 M

The total market value of all of Myomo, Inc.'s shares at today's price (share price × number of shares), smaller than 74% of Healthcare companies in United States. PosiCap size class: Micro Cap.

Net worth (book value)

$6 M

What Myomo, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).

Book value per share

$0.15

Net worth divided by the number of shares. The share price of $1.22 is 8.3 times this, which is the P/B above.

Return on equity (ROE)

-123.8%

Myomo, Inc. lost 123.8% of its shareholders' money over the last year, lower than 77% of Healthcare companies in United States.

Owes vs Owns

0.84×

Myomo, Inc. owes $0.84 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.

Dividend yield

None

Myomo, Inc. does not currently pay a dividend.

Revenue growth

+26%

Revenue rose 26% in the year to Dec 2025, and grew 38% a year on average over 3 years.

Profit growth

Loss

Myomo, Inc. made a loss in each of the last two years.

Profit margin

-38.1%

Myomo, Inc. lost $38 for every $100 of revenue.

Interest cover

Not covered

Myomo, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.

Cash vs debt

Net debt

Myomo, Inc. had $1 M more debt than cash (net debt) at Dec 2025.

Questions

How is P/B calculated on PositoAI?

P/B is market cap divided by net worth from the latest balance sheet. For Myomo, Inc.: $48 M ÷ $6 M (30 Jun 2026) = 8.3.

What is Myomo, Inc.'s return on equity?

Myomo, Inc. lost 123.8% of its shareholders' money over the last year, lower than 77% of Healthcare companies in United States.

How much does Myomo, Inc. owe compared with what it owns?

Myomo, Inc. owes $0.84 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.

Does Myomo, Inc. pay a dividend?

No. Myomo, Inc. does not currently pay a dividend.

Is Myomo, Inc.'s revenue growing?

Revenue rose 26% in the year to Dec 2025, and grew 38% a year on average over 3 years.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.